
    
      The Amulet IDE trial is a prospective, randomized, multi-center active control worldwide
      trial, designed to evaluate the safety and effectiveness of the AMPLATZER™ Amulet™ Left
      Atrial Appendage Occluder. Subjects will be randomized in a 1:1 ratio between the Amulet LAA
      occlusion device (treatment) or a Boston Scientific WATCHMAN® LAA closure device (Control).
      The trial will be conducted at up to 150 sites worldwide. All enrolled subjects will follow
      the protocol-required tests and assessments at each scheduled follow-up visit.
    
  